1
|
Purandare N, Gomez-Lopez N, Arenas-Hernandez M, Galaz J, Romero R, Xi Y, Fribley AM, Grossman LI, Aras S. The MNRR1 activator nitazoxanide abrogates lipopolysaccharide-induced preterm birth in mice. Placenta 2023; 140:66-71. [PMID: 37544161 PMCID: PMC10529525 DOI: 10.1016/j.placenta.2023.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 07/05/2023] [Accepted: 07/07/2023] [Indexed: 08/08/2023]
Abstract
Intra-amniotic inflammation leading to preterm birth is one of the leading causes of neonatal morbidity and mortality. We recently reported that the mitochondrial levels of MNRR1 (Mitochondrial Nuclear Retrograde, Regulator 1; also called CHCHD2, AAG10, or PARK22), an important bi-organellar regulator of cellular function, are reduced in the context of inflammation and that genetic and pharmacological increases in MNRR1 levels can counter the inflammatory profile. Herein, we show that nitazoxanide, a clinically approved drug, is an activator of MNRR1 and abrogates preterm birth in a well-characterized murine model caused by intra-amniotic lipopolysaccharide (LPS) injection.
Collapse
Affiliation(s)
- Neeraja Purandare
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA
| | - Nardhy Gomez-Lopez
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA; Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, 48201, USA; Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Marcia Arenas-Hernandez
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Jose Galaz
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Roberto Romero
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, 48104, USA; Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, 48824, USA
| | - Yue Xi
- Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Andrew M Fribley
- Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, 48201, USA
| | - Lawrence I Grossman
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA.
| | - Siddhesh Aras
- Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD 20892, USA; Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, 48201, USA
| |
Collapse
|
2
|
Ghafouri M, Gauss CB, Fribley AM. HTS Identification of Activators and Inhibitors of Endoplasmic Reticulum (ER) Stress and the Unfolded Protein Response (UPR). Methods Mol Biol 2022; 2378:317-327. [PMID: 34985709 DOI: 10.1007/978-1-0716-1732-8_20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
The identification of small molecules and natural product extracts that enhance or interfere with the productivity of protein folding in the endoplasmic reticulum (ER) has the potential to improve a wide variety of human pathologies. Every protein that is destined for a lysosome, integral to the cell membrane, or secreted, is folded, post-translationally modified, and exported to the cytoplasm from the ER-Golgi complex. The following protocols have successfully employed several high-fidelity cell-based luciferase high-throughput screens (HTS) to identify activators and inhibitors of ER stress and the unfolded protein response (UPR).
Collapse
Affiliation(s)
- Mehrnoosh Ghafouri
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
| | - Chester B Gauss
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
| | - Andrew M Fribley
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA.
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA.
- Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
| |
Collapse
|
3
|
Cole DW, Svider PF, Shenouda KG, Lee PB, Yoo NG, McLeod TM, Mutchnick SA, Yoo GH, Kaufman RJ, Callaghan MU, Fribley AM. Targeting the unfolded protein response in head and neck and oral cavity cancers. Exp Cell Res 2019; 382:111386. [PMID: 31075256 DOI: 10.1016/j.yexcr.2019.04.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2018] [Revised: 03/25/2019] [Accepted: 04/05/2019] [Indexed: 12/18/2022]
Abstract
Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by many of these compounds, the authors are currently unaware of any instance whereby a cancer drug was developed with the UPR as the intended target. With the essential role of the UPR as a driving force in the genesis and maintenance of the malignant phenotype, a great number of pre-clinical studies have surged into the medical literature describing the ability of dozens of compounds to induce UPR signaling in a myriad of cancer models. The focus of the current work is to review the literature and explore the role of the UPR as a mediator of chemotherapy-induced cell death in squamous cell carcinomas of the head and neck (HNSCC) and oral cavity (OCSCC), with an emphasis on preclinical studies.
Collapse
Affiliation(s)
- Daniel W Cole
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Peter F Svider
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Kerolos G Shenouda
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Paul B Lee
- Oakland University William Beaumont School of Medicine, Rochester Hills, Michigan, USA
| | - Nicholas G Yoo
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Thomas M McLeod
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Sean A Mutchnick
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - George H Yoo
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - Randal J Kaufman
- Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Michael U Callaghan
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Children's Hospital of Michigan, Detroit Medical Center, Detroit, MI, USA
| | - Andrew M Fribley
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; Children's Hospital of Michigan, Detroit Medical Center, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.
| |
Collapse
|
4
|
Shah O'Brien P, Xi Y, Miller JR, Brownell AL, Zeng Q, Yoo GH, Garshott DM, O'Brien MB, Galinato AE, Cai P, Narula N, Callaghan MU, Kaufman RJ, Fribley AM. Disulfiram (Antabuse) Activates ROS-Dependent ER Stress and Apoptosis in Oral Cavity Squamous Cell Carcinoma. J Clin Med 2019; 8:jcm8050611. [PMID: 31064122 PMCID: PMC6571807 DOI: 10.3390/jcm8050611] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 04/29/2019] [Accepted: 04/30/2019] [Indexed: 02/06/2023] Open
Abstract
A paucity of advances in the development of novel therapeutic agents for squamous cell carcinomas of the head and neck, oral cavity (OSCC) and oropharynx, has stagnated disease free survival rates over the past two decades. Although immunotherapies targeted against checkpoint inhibitors such as PD-1 or CTLA-4 are just now entering the clinic for late stage disease with regularity the median improvement in overall survival is only about three months. There is an urgent unmet clinical need to identify new therapies that can be used alone or in combination with current approaches to increase survival by more than a few months. Activation of the apoptotic arm of the unfolded response (UPR) with small molecules and natural products has recently been demonstrated to be a productive approach in pre-clinical models of OSCC and several other cancers. The aim of current study was to perform a high throughput screen (HTS) with a diverse chemical library to identify compounds that could induce CHOP, a component of the apoptotic arm of the UPR. Disulfiram (DSF, also known as Antabuse) the well-known aversion therapy used to treat chronic alcoholism emerged as a hit that could generate reactive oxygen species, activate the UPR and apoptosis and reduce proliferation in OSCC cell cultures and xenografts. A panel of murine embryonic fibroblasts null for key UPR intermediates (e.g., Chop and Atf4) was resistant to DSF suggesting that an intact UPR is a key element of the mechanism regulating the antiproliferative effects of DSF.
Collapse
Affiliation(s)
- Priyanka Shah O'Brien
- Department of Otolaryngology⁻Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Yue Xi
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Justin R Miller
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Amy L Brownell
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Qinghua Zeng
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
| | - George H Yoo
- Department of Otolaryngology⁻Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USA.
- Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Danielle M Garshott
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Matthew B O'Brien
- Henry Ford Hospital, Diagnostic Radiology Residency, Detroit, MI 48202, USA.
| | - Anthony E Galinato
- Henry Ford Hospital, Diagnostic Radiology Residency, Detroit, MI 48202, USA.
| | - Peter Cai
- Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Neha Narula
- Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Michael U Callaghan
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
- Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | - Randal J Kaufman
- Degenerative Diseases Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
| | - Andrew M Fribley
- Department of Otolaryngology⁻Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USA.
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- Wayne State University School of Medicine, Detroit, MI 48201, USA.
- Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| |
Collapse
|
5
|
Ramsey T, Hojjat H, Yuhan B, Svider PF, Eloy JA, Folbe AJ, Raza SN, Fribley AM. Disparities in impact of nasopharyngeal cancer: An analysis of global health burden. Laryngoscope 2019; 129:2482-2486. [PMID: 30889288 DOI: 10.1002/lary.27532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 07/27/2018] [Accepted: 08/01/2018] [Indexed: 11/09/2022]
Abstract
OBJECTIVES Nasopharyngeal carcinoma has a unique worldwide racial and geographic distribution. Our objective was to evaluate socioeconomic disparities in the burden of nasopharyngeal cancer (NPC) between endemic and nonendemic regions. METHODS To demonstrate trends regarding societal burden of NPC and socioeconomic development, national disability-adjusted life year (DALY) rates and human development indices (HDI) between 1990 and 2015 were evaluated. Countries were divided based on the endemic versus nonendemic presence of NPC and further analyzed by HDI status as specified by the United Nations Development Program. Gini coefficients and concentration index were used to evaluate global equality in NPC burden over this period. RESULTS Age-standardized DALYs dropped from 36.1 in 1990 to 26.5 in 2015 (26.6% decline) (r = -0.991, P < 0.001). Lower socioeconomic countries harbored greater NPC burden upon controlling by endemic and nonendemic regions, as demonstrated by progressively negative concentration indexes. Health inequality was greater in nonendemic countries than in endemic countries (P < 0.01). CONCLUSION To our knowledge, this is the first study to investigate socioeconomic-related changes in NPC burden using statistical tools such as the Gini coefficient and concentration index. Although the burden of NPC has steadily decreased, there remain persistent inequalities associated with socioeconomic disparities. Nasopharyngeal cancer burden is more pronounced in countries with lower HDI. Our results reinforce the importance of increasing resources for developing countries and continuing inquiry into the screening, diagnosis, and management of NPC. LEVEL OF EVIDENCE NA Laryngoscope, 129:2482-2486, 2019.
Collapse
Affiliation(s)
- Tam Ramsey
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan
| | - Houmehr Hojjat
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan
| | - Brian Yuhan
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan.,Beaumont Health System, Royal Oak, Michigan
| | - Peter F Svider
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan
| | - Jean Anderson Eloy
- Department of Otolaryngology-Head and Neck Surgery, Newark, New Jersey, U.S.A.,Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Newark, New Jersey, U.S.A
| | - Adam J Folbe
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit.,Beaumont Health System, Royal Oak, Michigan
| | - Syed Naweed Raza
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan
| | - Andrew M Fribley
- Department of Otolaryngology-Head and Neck Surgery, Royal Oak, Michigan
| |
Collapse
|
6
|
Fribley AM, Xi Y, Makris C, Alves-de-Souza C, York R, Tomas C, Wright JLC, Strangman WK. Identification of Portimine B, a New Cell Permeable Spiroimine That Induces Apoptosis in Oral Squamous Cell Carcinoma. ACS Med Chem Lett 2019; 10:175-179. [PMID: 30783499 DOI: 10.1021/acsmedchemlett.8b00473] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 12/26/2018] [Indexed: 02/07/2023] Open
Abstract
Spiroimines are a class of compounds produced by marine dinoflagellates with a wide range of toxicity and therapeutic potential. The smallest of the cyclic imines, portimine, is far less toxic than other known members in several animal models. Portimine has also been shown to induce apoptosis and reduce the growth of a variety of cancer cell lines at low nanomolar concentrations. In an effort to discover new spiroimines, the current study undertook a metabolomic analysis of cultures of cyclic imine-producing dinoflagellates, and a new analog of portimine was discovered in which the five-membered cyclic ether is open. Further scrutiny with human oral cavity squamous cell carcinoma (OCSCC) cell lines revealed that the open ring congener was less potent than portimine A but could still lead to the accumulation of apoptotic gene transcripts, fragment genomic DNA, and reduce cancer cell proliferation in the range of 100-200 nM.
Collapse
Affiliation(s)
- Andrew M. Fribley
- Carman and Ann Adams Department of Pediatrics, Division of Hematology/Oncology and the Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University, 421 East Canfield, Detroit, Michigan 48201, United States
| | - Yue Xi
- Carman and Ann Adams Department of Pediatrics, Division of Hematology/Oncology and the Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University, 421 East Canfield, Detroit, Michigan 48201, United States
| | - Christina Makris
- Department of Chemistry and Biochemistry, University of North Carolina Wilmington, 601 South College Road, Wilmington, North Carolina 28403, United States
| | - Catharina Alves-de-Souza
- Algal Resources Collection, MARBIONC at Crest Research Park, University of North Carolina Wilmington, 5600 Marvin Moss K. Lane, Wilmington, North Carolina 28409, United States
| | - Robert York
- Algal Resources Collection, MARBIONC at Crest Research Park, University of North Carolina Wilmington, 5600 Marvin Moss K. Lane, Wilmington, North Carolina 28409, United States
| | - Carmelo Tomas
- Algal Resources Collection, MARBIONC at Crest Research Park, University of North Carolina Wilmington, 5600 Marvin Moss K. Lane, Wilmington, North Carolina 28409, United States
| | - Jeffrey L. C. Wright
- Department of Chemistry and Biochemistry, University of North Carolina Wilmington, 601 South College Road, Wilmington, North Carolina 28403, United States
- Biomolecular Discovery Group, MARBIONC at Crest Research Park, University of North Carolina Wilmington, 5600 Marvin Moss K. Lane, Wilmington, North Carolina 28409, United States
| | - Wendy K. Strangman
- Biomolecular Discovery Group, MARBIONC at Crest Research Park, University of North Carolina Wilmington, 5600 Marvin Moss K. Lane, Wilmington, North Carolina 28409, United States
| |
Collapse
|
7
|
Ramsey T, Guo E, Svider PF, Lin H, Syeda S, Raza SN, Fribley AM. Laryngeal cancer: Global socioeconomic trends in disease burden and smoking habits. Laryngoscope 2018; 128:2039-2053. [PMID: 29508408 DOI: 10.1002/lary.27068] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2017] [Revised: 11/01/2017] [Accepted: 11/22/2017] [Indexed: 01/04/2023]
Abstract
OBJECTIVES/HYPOTHESIS To characterize health burden and determine the associated level of equality of laryngeal carcinoma (LC) burden at a global level. METHODS One hundred eighty-four countries were organized by socioeconomic status using Human Development Index (HDI) categorizations provided by the United Nations Development Program. Disability-adjusted life years (DALYs), obtained from The Global Health Data Exchange, were calculated and compared between each HDI category for the period from 1990 to 2015. Equality of LC burden was then evaluated with concentration indices. RESULTS Global LC burden, as measured by age-standardized DALYs, has improved significantly over the 25-year period studied. This burden has declined for very high, high, and medium HDI countries, whereas it has remained unchanged for low HDI countries. The majority of LC global burden was found in high socioeconomic countries before 2010 and has shifted toward low socioeconomic countries, as indicated by concentration indices. Over the last 25 years, Central and Eastern Europe continue to have the largest disease burden in the world. CONCLUSION This is the first analysis that we are aware of investigating health disparities of LC at a global level. The global burden of the disease has declined, which is a trend corresponding with significantly reduced smoking behaviors in developed countries. Although the global inequality gap decreased between 2010 and 2015, there remain reasons for concern. Smoking continues to trend upward in low socioeconomic countries, which could increase LC burden in low socioeconomic countries in the near future. A new global initiative directed toward low socioeconomic countries may yield dividends in preventing subsequent disparities in the LC burden. LEVEL OF EVIDENCE 4. Laryngoscope, 128:2039-2053, 2018.
Collapse
Affiliation(s)
- Tam Ramsey
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A
| | - Eric Guo
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A
| | - Peter F Svider
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A
| | - Hosheng Lin
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.,John Dingell VA Medical Center, Detroit, Michigan, U.S.A
| | - Sara Syeda
- Department of Economics, Wayne State University, Detroit, Michigan, U.S.A
| | - S Naweed Raza
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| | - Andrew M Fribley
- Department of Otolaryngology-Head and Neck Surgery, Detroit, Michigan, U.S.A.,Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| |
Collapse
|
8
|
Ren B, Liu H, Gao H, Liu S, Zhang Z, Fribley AM, Callaghan MU, Xu Z, Zeng Q, Li Y. Celastrol induces apoptosis in hepatocellular carcinoma cells via targeting ER-stress/UPR. Oncotarget 2017; 8:93039-93050. [PMID: 29190976 PMCID: PMC5696242 DOI: 10.18632/oncotarget.21750] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 08/27/2017] [Indexed: 01/19/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is one of the most serious and deadly diseases worldwide with limited options for effective treatment. Biomarker-based active compound targeting therapy may shed some light on novel drugs for HCC. The endoplasmic reticulum (ER) stress and unfolded protein response (UPR) play important roles in the regulation of cell fate and have become novel signaling targets for the development of anticancer drugs. Celastrol, a triterpene from traditional Chinese medicine, has been reported to possess anti-tumor effects on various cancers. We, along with several other research groups, have recently reported that UPR was induced by celastrol in several different cancers, including hepatocellular carcinoma. However, UPR status in HCC still remains unclear. The role of ER stress and autophagy in response to celastrol also has yet to be elucidated. Our results demonstrated that celastrol could cause G2/M phase rest and inhibit proliferation in HepG2 and Bel7402. Exposure to celastrol resulted in the activation of the intrinsic apoptotic pathway, via ER stress and the UPR. In murine syngeneic model studies celastrol inhibited H22 tumor growth via the induction of ER stress and apoptosis. Our study suggests that celastrol is a potential drug for HCC therapy via targeting ER-stress/UPR.
Collapse
Affiliation(s)
- Bo Ren
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
| | - Hui Liu
- Pathology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China
| | - Hang Gao
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
| | - Shutong Liu
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
| | - Zehui Zhang
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
| | - Andrew M. Fribley
- Carman and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Wayne State University, Detroit, MI 48201, USA
- Molecular Therapeutics Program, Karmanos Cancer Institute, Detroit, MI 48201, USA
| | - Michael U. Callaghan
- Carman and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Wayne State University, Detroit, MI 48201, USA
| | - Zhixiang Xu
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Qinghua Zeng
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
- Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Yulin Li
- The Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun 130021, China
| |
Collapse
|
9
|
Rayess HM, Nissan M, Gupta A, Carron MA, Raza SN, Fribley AM. Oropharyngeal lymphoma: A US population based analysis. Oral Oncol 2017; 73:147-151. [PMID: 28939067 DOI: 10.1016/j.oraloncology.2017.08.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Revised: 08/22/2017] [Accepted: 08/27/2017] [Indexed: 01/28/2023]
Abstract
OBJECTIVES To describe the epidemiology and analyze factors determinant of survival in patients with oropharyngeal lymphoma, using the Surveillance Epidemiology and End Results (SEER) database. METHODS 2504 patients with oropharyngeal lymphoma were identified using the most recent SEER database entry from 1976 to 2016. Demographic information, Ann Arbor stage, tumor histopathology and location were collected. Multivariate analysis was used to analyze patient and tumor characteristics associated with survival. RESULTS The mean age of the patients studied was 60.5years, 58.4% of the subjects were male and 81% were white. Diffuse large B cell lymphoma (DLBCL) was the most common histologic subtype involving 56.9% of cases. The most common subsite of origin was the tonsil, with 71% of lymphomas originating from there. The association of survival with stage, age, tumor location, presence of B symptoms, tumor pathology, gender and race was analyzed using multivariate regression. Decreased survival was significantly associated with patient age p<0.0001, Ann Arbor staging p=0.005, the presence of B symptoms p=0.003 and tumor histopathology (T cell tumors) p=0.01. Patients with tumors originating from the soft palate were significantly more likely to die asa result of their disease p=0.03. CONCLUSION Oropharyngeal lymphoma most commonly originates from the tonsil. DLBCL is the most common subtype and has a good prognosis. The presence of B symptoms, tumors originating from the soft palate and patients with T cell tumors have the worst prognosis. This information can potentially be of great utility to the head and neck surgeon discussing prognosis with patients suffering from oropharyngeal lymphoma.
Collapse
Affiliation(s)
- Hani M Rayess
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA.
| | - Michael Nissan
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Amar Gupta
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - Michael A Carron
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Division of Facial Plastics and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, USA
| | - S Naweed Raza
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - Andrew M Fribley
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA; Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| |
Collapse
|
10
|
Felt JR, Yurkovich C, Garshott DM, Kamat D, Farooqi A, Fribley AM, Callaghan MU, Hebert K. The Utility of Real-Time Quantitative Polymerase Chain Reaction Genotype Detection in the Diagnosis of Urinary Tract Infections in Children. Clin Pediatr (Phila) 2017; 56:912-919. [PMID: 28436231 DOI: 10.1177/0009922817706144] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Urinary tract infections (UTIs) are the most common serious bacterial infection in children with significant morbidity with delayed diagnosis. Polymerase chain reaction (PCR) is very accurate in detecting bacteria and widely available, but has never been evaluated to detect UTIs in children. To assess the utility of PCR as a rapid diagnostic tool, we conducted a prospective cohort study of 193 urine samples from children younger than 36 months undergoing evaluation for UTI in the emergency department over a 10-month period. A quantification cycle (Cq) threshold of 26.15 identified all Escherichia coli positive samples with sensitivity and specificity of 100% and 99.5%, respectively (95% CI = 71.5%-100% and 97.9%-99.5%, respectively). A Cq threshold of 19.03 identified E coli infections >100 000 colony forming units/mL with sensitivity and specificity of 100% (95% CI = 72.2%-100% and 98.6%-100%, respectively). PCR is very accurate in diagnosing E coli UTIs in young children and could be useful as a rapid diagnostic tool.
Collapse
Affiliation(s)
- Jon R Felt
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| | - Chelsey Yurkovich
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| | | | - Deepak Kamat
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| | - Ahmad Farooqi
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| | - Andrew M Fribley
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| | | | - Katherine Hebert
- 1 Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
| |
Collapse
|
11
|
Blasco MA, Svider PF, Raza SN, Jacobs JR, Folbe AJ, Saraf P, Eloy JA, Baredes S, Fribley AM. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. Laryngoscope 2017; 127:2565-2569. [PMID: 28581126 DOI: 10.1002/lary.26629] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 02/16/2017] [Accepted: 03/21/2017] [Indexed: 12/29/2022]
Abstract
OBJECTIVES Despite dramatic developments in drugs established for other malignancies, historically there have been few novel systemic agents available for the management of head and neck squamous cell carcinoma (HNSCC). However, the last decade has observed increased interest in targeted therapies for HNSCC. In 2006, cetuximab became the first major drug for HNSCC to gain Food and Drug Administration (FDA) approval in 3 decades. Recently, both pembrolizumab and nivolumab gained FDA approval for treatment of recurrent or metastatic HNSCC, and trials for other indications in HNSCC are actively underway. As older agents including cisplatin and 5-fluorouracil continue to play a significant role in the management of advanced HNSCC, an understanding of their legacy is paramount. This historical review is not meant to exhaustively catalog every finding relating to HNSCC systemic therapy, but rather is meant to highlight important advances. DATA SOURCES Case series and clinical trials available in the literature. REVIEW METHODS Historically significant series and trials evaluating HNSCC systemic therapy were evaluated. RESULTS Standard regimens employed today are largely comprised of drugs discovered over 4 decades ago, although a number of recent phase III clinical trials have shown great promise, leading to the adoption of several new chemotherapeutic agents and treatment strategies. CONCLUSIONS These findings reinforce the importance of supporting further HNSCC drug discovery as modern treatment strategies using systemic therapy have resulted in measurable improvements in oncologic outcomes. Laryngoscope, 127:2565-2569, 2017.
Collapse
Affiliation(s)
- Michael A Blasco
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - Peter F Svider
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - S Naweed Raza
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| | - John R Jacobs
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| | - Adam J Folbe
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.,Department of Neurosurgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - Pankhoori Saraf
- Department of Medicine, Division of Hematology and Oncology, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Jean Anderson Eloy
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Newark, New Jersey, U.S.A.,Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A
| | - Soly Baredes
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, U.S.A.,Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Newark, New Jersey, U.S.A
| | - Andrew M Fribley
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.,Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| |
Collapse
|
12
|
Fribley AM, Svider PF, Warner BM, Garshott DM, Raza SN, Kirkwood KL. Recent Trends in Oral Cavity Cancer Research Support in the United States. J Dent Res 2017; 96:17-22. [PMID: 28033064 DOI: 10.1177/0022034516680556] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The objectives were to characterize oral cavity cancer (OCC) funding from the National Institutes of Health (NIH) with a secondary aim of comparing NIH support provided to OCC and other malignancies. NIH awards supporting OCC inquiry from 2000 to 2014 were accessed from the NIH RePORTER database. These data were used to evaluate temporal trends and the role of human papilloma virus and to determine the academic training and professional profiles of the principal investigators. Comparison of 2014 funding levels with other malignancies was also performed, controlling for incidence. Overall funding totals decreased considerably after 2009. Funding administered through the National Institute of Dental and Craniofacial Research (NIDCR) was 6.5 times greater than dollars awarded by the National Cancer Institute in 2000. During the period evaluated, NIDCR support decreased in most years, while National Cancer Institute support increased and approached NIDCR funding levels. Funding for human papilloma virus-related projects gradually rose, from 3.4% of dollars in 2000 to 2004 to 6.2% from 2010 to 2014 ( P < 0.05). A majority of principal investigators had a PhD omnia solus (57%), and 13% possessed dual PhD/clinical degrees. Among clinicians with specialty training, otolaryngologists and oral/maxillofacial pathologists garnered the most funding. OCC had a 2014 funding:incidence ratio of $785, much lower than for other malignancies. There has been increased volatility in funding support in recent years possibly due to budget cuts and sequestration. The National Cancer Institute has played an increasingly important role in supporting OCC research, concomitant with decreasing NIDCR support. Our findings suggest that OCC is underfunded relative to other non-oral cavity malignancies, indicating a need to increase the focus on rectifying the disparity.
Collapse
Affiliation(s)
- A M Fribley
- 1 Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA.,2 Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.,3 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA.,4 Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - P F Svider
- 3 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA
| | - B M Warner
- 5 Department of Oral and Maxillofacial Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - D M Garshott
- 1 Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
| | - S N Raza
- 3 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, MI, USA.,4 Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
| | - K L Kirkwood
- 6 Department of Oral Health Sciences and the Center for Oral Health Research, Medical University of South Carolina, Charleston, SC, USA.,7 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.,8 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA
| |
Collapse
|
13
|
Southwood CM, Garshott DM, Richardson CR, Seraji-Bozorgzad N, Fribley AM, Gow A. Dimethyl fumarate ameliorates myoclonus stemming from protein misfolding in oligodendrocytes. J Neurochem 2017; 142:103-117. [PMID: 28382685 DOI: 10.1111/jnc.14035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 03/24/2017] [Accepted: 03/29/2017] [Indexed: 12/01/2022]
Abstract
Multiple sclerosis (MS) is considered a primary autoimmune disease; however, this view is increasingly being challenged in basic and clinical science arenas because of the growing body of clinical trials' data showing that exclusion of immune cells from the CNS only modestly slows disease progression to disability. Accordingly, there is significant need for expanding the scope of potential disease mechanisms to understand the etiology of MS. Concomitantly, the use of a broader range of pre-clinical animal models for characterizing existing efficacious clinical treatments may elucidate additional or unexpected mechanisms of action for these drugs that augment insight into MS etiology. Herein, we explore the in vivo mechanism of action of dimethyl fumarate, which has been shown to suppress oxidative stress and immune cell responses in psoriasis and MS. Rather than studying this compound in the context of an experimental autoimmune-induced attack on the CNS, we have used a genetic model of hypomyelination, male rumpshaker (rsh) mice, which exhibit oligodendrocyte metabolic stress and startle-induced subcortical myoclonus during development and into adulthood. We find that myoclonus is reduced 30-50% in treated mutants but we do not detect substantial changes in metabolic or oxidative stress response pathways, cytokine modulation, or myelin thickness (assessed by anova). All procedures involving vertebrate animals in this study were reviewed and approved by the IACUC committee at Wayne State University.
Collapse
Affiliation(s)
- Cherie M Southwood
- Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA
| | - Danielle M Garshott
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
| | - Chelsea R Richardson
- Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA
| | | | - Andrew M Fribley
- Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA
| | - Alexander Gow
- Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.,Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA.,Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
| |
Collapse
|
14
|
Blasco MA, Svider PF, Tenbrunsel T, Vellaichamy G, Yoo GH, Fribley AM, Raza SN. Recent trends in oropharyngeal cancer funding and public interest. Laryngoscope 2017; 127:1345-1350. [PMID: 28397339 DOI: 10.1002/lary.26471] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 10/12/2016] [Accepted: 11/17/2016] [Indexed: 11/08/2022]
Abstract
OBJECTIVES/HYPOTHESIS The incidence of oropharyngeal cancer (OPC) has increased in the United States. This has been driven by an increase in human papillomavirus (HPV)-positive OPC. Our objective is to determine trends in National Institutes (NIH)-supported research funding and public interest in OPC. METHODS The NIH Research Portfolio Online Reporting Tools database was evaluated for projects related to OPC between 2004 and 2015. Projects were evaluated for total funding, relation to HPV, principal investigator departmental affiliation and degree, and NIH agency or center responsible for grant. The Google Trends database was evaluated for relative Internet search popularity of oropharyngeal cancer and related search terms between 2004 and 2015. RESULTS In terms of NIH funding, 100 OPC-related projects representing 242 grant years and $108.5 million were funded between 2004 and 2015. Total NIH funding for OPC projects increased from $167,406 in 2004 to $16.2 million in 2015. Funding for HPV-related OPC increased from less than $2 million yearly between 2004 and 2010 up to $12.7 million in 2015. Principal investigators related to radiation oncology ($41.8 million) and with doctor of medicine degrees ($52.8 million) received the largest share of total funding. Relative Internet search popularity for oropharyngeal cancer has increased from 2004 to 2015 compared to control cancer search terms. CONCLUSION Increased public interest and NIH funding has paralleled the rising incidence of OPC. NIH funding has been driven by projects related to the role of HPV in OPC. LEVEL OF EVIDENCE 2c. Laryngoscope, 127:1345-1350, 2017.
Collapse
Affiliation(s)
- Michael A Blasco
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - Peter F Svider
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - Troy Tenbrunsel
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - Gautham Vellaichamy
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A
| | - George H Yoo
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| | - Andrew M Fribley
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A.,Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| | - S Naweed Raza
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.,Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, U.S.A
| |
Collapse
|
15
|
Abstract
Despite a considerable expansion in our therapeutic repertoire for management of other malignancies, mortality from head and neck cancer (HNC) has not significantly improved in recent decades. Upon normalizing National Institutes of Health-awarded R01 and R01-equivalent grants by incidence, thyroid cancer ($214) and HNC ($1329) received the fewest funding dollars. Upon adjusting funding totals by mortality, HNC was 7th out of 9 cancers evaluated ($6138). These findings highlight HNC as an underfunded disease versus other cancers. As data detailing grant applications (including unsuccessful grants) are not publicly available, it is not clear if these disparities stem from fewer applications or fewer opportunities. Our hope is that this commentary will spur further investigation into strategies to increase HNC inquiry and funding for trainees as well as early-stage and established investigators.
Collapse
Affiliation(s)
- Peter F Svider
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA
| | - Michael A Blasco
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA
| | - S Naweed Raza
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
| | - Mahdi Shkoukani
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.,3 Section of Otolaryngology, Department of Surgery, John D. Dingell VA Medical Center, Detroit, Michigan, USA
| | - Ammar Sukari
- 2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.,4 Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA
| | - George H Yoo
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
| | - Adam J Folbe
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
| | - Ho-Sheng Lin
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.,3 Section of Otolaryngology, Department of Surgery, John D. Dingell VA Medical Center, Detroit, Michigan, USA
| | - Andrew M Fribley
- 1 Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.,2 Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA.,5 Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.,6 Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
| |
Collapse
|
16
|
Sidhu A, Miller JR, Tripathi A, Garshott DM, Brownell AL, Chiego DJ, Arevang C, Zeng Q, Jackson LC, Bechler SA, Callaghan MU, Yoo GH, Sethi S, Lin HS, Callaghan JH, Tamayo-Castillo G, Sherman DH, Kaufman RJ, Fribley AM. Borrelidin Induces the Unfolded Protein Response in Oral Cancer Cells and Chop-Dependent Apoptosis. ACS Med Chem Lett 2015; 6:1122-7. [PMID: 26617965 DOI: 10.1021/acsmedchemlett.5b00133] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 09/08/2015] [Indexed: 12/12/2022] Open
Abstract
Oral squamous cell carcinoma (OSCC) is the most common cancer affecting the oral cavity, and US clinics will register about 30,000 new patients in 2015. Current treatment modalities include chemotherapy, surgery, and radiotherapy, which often result in astonishing disfigurement. Cancers of the head and neck display enhanced levels of glucose-regulated proteins and translation initiation factors associated with endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Previous work demonstrated that chemically enforced UPR could overwhelm these adaptive features and selectively kill malignant cells. The threonyl-tRNA synthetase (ThRS) inhibitor borrelidin and two congeners were discovered in a cell-based chemical genomic screen. Borrelidin increased XBP1 splicing and led to accumulation of phosphorylated eIF2α and UPR-associated genes, prior to death in panel of OSCC cells. Murine embryonic fibroblasts (MEFs) null for GCN2 and PERK were less able to accumulate UPR markers and were resistant to borrelidin. This study demonstrates that UPR induction is a feature of ThRS inhibition and adds to a growing body of literature suggesting ThRS inhibitors might selectively target cancer cells.
Collapse
Affiliation(s)
- Alpa Sidhu
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Justin R. Miller
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Ashootosh Tripathi
- Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Danielle M. Garshott
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Amy L. Brownell
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Daniel J. Chiego
- Cariology,
Restorative Sciences and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan 48109, United States
| | - Carl Arevang
- Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Qinghua Zeng
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Leah C. Jackson
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Shelby A. Bechler
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - Michael U. Callaghan
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
| | - George H. Yoo
- Department
of Otolaryngology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, United States
| | - Seema Sethi
- Department
of Pathology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, United States
| | - Ho-Sheng Lin
- Department
of Otolaryngology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, United States
| | - Joseph H. Callaghan
- School of
Business Administration, Oakland University, Rochester, Michigan 48309, United States
| | - Giselle Tamayo-Castillo
- Instituto
Nacional de Biodiversidad, CIPRONA-Escuela de Química, Universidad de Costa Rica, 3100 Heredia, Costa Rica
| | - David H. Sherman
- Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Randal J. Kaufman
- Degenerative Disease Research Program,
Center for Cancer Research, Sanford
- Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Andrew M. Fribley
- Carmen
and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, United States
- Department
of Otolaryngology, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, United States
- Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, United States
| |
Collapse
|
17
|
Cruz PG, Fribley AM, Miller JR, Larsen MJ, Schultz PJ, Jacob RT, Tamayo-Castillo G, Kaufman RJ, Sherman DH. Novel Lobophorins Inhibit Oral Cancer Cell Growth and Induce Atf4- and Chop-Dependent Cell Death in Murine Fibroblasts. ACS Med Chem Lett 2015; 6:877-81. [PMID: 26288688 DOI: 10.1021/acsmedchemlett.5b00127] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 07/06/2015] [Indexed: 12/15/2022] Open
Abstract
As part of the International Cooperative Biodiversity Groups (ICBG) Program, we were interested in identifying biologically active unfolded protein response (UPR) inducing compounds from marine microorganisms isolated from Costa Rican biota. With this aim in mind we have now generated more than 33,000 unique prefractionated natural product extracts from marine and terrestrial organisms that have been submitted to the Center of Chemical Genomics (CCG) at the University of Michigan for high throughput screening (HTS). An effective complementary cell-based assay to identify novel modulators of UPR signaling was used for screening extracts. Active fractions were iteratively subjected to reverse-phase HPLC chromatographic analysis, and together with lobophorin A, B, E, and F (1-4), three new lobophorin congeners, designated as CR1 (5), CR2 (6), and CR3 (7) were isolated. Herein, we report that secondary assays revealed that the new lobophorins induced UPR-associated gene expression, inhibited oral squamous cell carcinoma cell growth, and led to UPR-dependent cell death in murine embryonic fibroblast (MEF) cells.
Collapse
Affiliation(s)
- Patricia G. Cruz
- Center for Chemical Genomics, Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109-2216, United States
| | - Andrew M. Fribley
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Program, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Justin R. Miller
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Program, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Martha J. Larsen
- Center for Chemical Genomics, Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109-2216, United States
| | - Pamela J. Schultz
- Center for Chemical Genomics, Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109-2216, United States
| | - Renju T. Jacob
- Center for Chemical Genomics, Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109-2216, United States
| | - Giselle Tamayo-Castillo
- Instituto Nacional de Biodiversidad (INBio), Heredia, Costa Rica & CIPRONA-Escuela de Química, Universidad de Costa Rica (UCR), 2061-San José, Costa Rica
| | - Randal J. Kaufman
- Degenerative
Disease Research Program, Center for Cancer Research, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - David H. Sherman
- Center for Chemical Genomics, Life Sciences Institute and Departments of Medicinal Chemistry, Chemistry, Microbiology & Immunology, University of Michigan, Ann Arbor, Michigan 48109-2216, United States
| |
Collapse
|
18
|
Xi Y, Gao H, Callaghan MU, Fribley AM, Garshott DM, Xu ZX, Zeng Q, Li YL. Induction of BCL2-Interacting Killer, BIK, is Mediated for Anti-Cancer Activity of Curcumin in Human Head and Neck Squamous Cell Carcinoma Cells. J Cancer 2015; 6:327-32. [PMID: 25767602 PMCID: PMC4349872 DOI: 10.7150/jca.11185] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 01/03/2015] [Indexed: 02/07/2023] Open
Abstract
Naturally occurring diarylheptanoid curcumin (CUR), a principal component of the Asian spice turmeric, has been shown to have anti-cancer effects in many tumor types. However, a detailed mechanism regarding CUR induced tumor cell killing remain to be comprehensively explored. Using two head neck squamous cell carcinoma (HNSCC) cell lines FaDu (hypopharyngeal) and Cal27 (tongue), we demonstrated a novel mechanism by which CUR levies the cytotoxic effect. We found that CUR induced upregulation of pro-apoptotic Bik, down-regulation of survival signaling by AKT and NF-κB prior to the induction of the caspase-cascade reduction of cell proliferation, are primary mechanisms of CUR-induced cell death, thus providing insights into the anti-tumor activity of CUR in HNSCC cells.
Collapse
Affiliation(s)
- Yue Xi
- 1. The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China ; 2. Carmen and Ann Adams Department of Pediatrics, Department of Otolaryngology, Wayne State University, Detroit, MI 48201, USA
| | - Hang Gao
- 1. The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China
| | - Michael U Callaghan
- 2. Carmen and Ann Adams Department of Pediatrics, Department of Otolaryngology, Wayne State University, Detroit, MI 48201, USA
| | - Andrew M Fribley
- 2. Carmen and Ann Adams Department of Pediatrics, Department of Otolaryngology, Wayne State University, Detroit, MI 48201, USA ; 3. Molecular Therapeutics Program, Karmanos Cancer Institute, Detroit, MI 48201, USA
| | - Danielle M Garshott
- 2. Carmen and Ann Adams Department of Pediatrics, Department of Otolaryngology, Wayne State University, Detroit, MI 48201, USA
| | - Zhi-Xiang Xu
- 1. The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China ; 4. Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
| | - Qinghua Zeng
- 1. The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China ; 4. Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
| | - Yu-Lin Li
- 1. The Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China
| |
Collapse
|
19
|
Flaherty DP, Miller JR, Garshott DM, Hedrick M, Gosalia P, Li Y, Milewski M, Sugarman E, Vasile S, Salaniwal S, Su Y, Smith LH, Chung TDY, Pinkerton AB, Aubé J, Callaghan MU, Golden JE, Fribley AM, Kaufman RJ. Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response. ACS Med Chem Lett 2014; 5:1278-1283. [PMID: 25530830 PMCID: PMC4266338 DOI: 10.1021/ml5003234] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 10/29/2014] [Indexed: 01/29/2023] Open
Abstract
![]()
Cellular proteins that fail to fold
properly result in inactive
or disfunctional proteins that can have toxic functions. The unfolded
protein response (UPR) is a two-tiered cellular mechanism initiated
by eukaryotic cells that have accumulated misfolded proteins within
the endoplasmic reticulum (ER). An adaptive pathway facilitates the
clearance of the undesired proteins; however, if overwhelmed, cells
trigger apoptosis by upregulating transcription factors such as C/EBP-homologous
protein (CHOP). A high throughput screen was performed directed at
identifying compounds that selectively upregulate the apoptotic CHOP
pathway while avoiding adaptive signaling cascades, resulting in a
sulfonamidebenzamide chemotype that was optimized. These efforts produced
a potent and selective CHOP inducer (AC50 = 0.8 μM;
XBP1 > 80 μM), which was efficacious in both mouse embryonic
fibroblast cells and a human oral squamous cell cancer cell line,
and demonstrated antiproliferative effects for multiple cancer cell
lines in the NCI-60 panel.
Collapse
Affiliation(s)
- Daniel P. Flaherty
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Justin R. Miller
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Danielle M. Garshott
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Michael Hedrick
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Palak Gosalia
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Yujie Li
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Monika Milewski
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Eliot Sugarman
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Stefan Vasile
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Sumeet Salaniwal
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Ying Su
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Layton H. Smith
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Thomas D. Y. Chung
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Anthony B. Pinkerton
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Jeffrey Aubé
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Michael U. Callaghan
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Jennifer E. Golden
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Andrew M. Fribley
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Randal J. Kaufman
- Program
in Degenerative Disease Research, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
20
|
Fribley AM, Miller JR, Brownell AL, Garshott DM, Zeng Q, Reist TE, Narula N, Cai P, Xi Y, Callaghan MU, Kodali V, Kaufman RJ. Celastrol induces unfolded protein response-dependent cell death in head and neck cancer. Exp Cell Res 2014; 330:412-422. [PMID: 25139619 DOI: 10.1016/j.yexcr.2014.08.014] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 08/06/2014] [Accepted: 08/09/2014] [Indexed: 11/29/2022]
Abstract
The survival rate for patients with oral squamous cell carcinoma (OSCC) has not seen marked improvement in recent decades despite enhanced efforts in prevention and the introduction of novel therapies. We have reported that pharmacological exacerbation of the unfolded protein response (UPR) is an effective approach to killing OSCC cells. The UPR is executed via distinct signaling cascades whereby an initial attempt to restore folding homeostasis in the endoplasmic reticulum during stress is complemented by an apoptotic response if the defect cannot be resolved. To identify novel small molecules able to overwhelm the adaptive capacity of the UPR in OSCC cells, we engineered a complementary cell-based assay to screen a broad spectrum of chemical matter. Stably transfected CHO-K1 cells that individually report (luciferase) on the PERK/eIF2α/ATF4/CHOP (apoptotic) or the IRE1/XBP1 (adaptive) UPR pathways, were engineered [1]. The triterpenoids dihydrocelastrol and celastrol were identified as potent inducers of UPR signaling and cell death in a primary screen and confirmed in a panel of OSCC cells and other cancer cell lines. Biochemical and genetic assays using OSCC cells and modified murine embryonic fibroblasts demonstrated that intact PERK-eIF2-ATF4-CHOP signaling is required for pro-apoptotic UPR and OSCC death following celastrol treatment.
Collapse
Affiliation(s)
- Andrew M Fribley
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA.
| | - Justin R Miller
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA
| | - Amy L Brownell
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA
| | - Danielle M Garshott
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA
| | - Qinghua Zeng
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA
| | - Tyler E Reist
- The Undergraduate Research Opportunities Program, University of Michigan, Ann Arbor, MI 48109, USA
| | - Neha Narula
- Wayne State University School of Medicine, Detroit, MI, USA
| | - Peter Cai
- Wayne State University School of Medicine, Detroit, MI, USA
| | - Yue Xi
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA
| | - Michael U Callaghan
- Carmen and Ann Adams Department of Pediatrics, Children׳s Hospital of Michigan, Detroit, MI 48201, USA; Wayne State University School of Medicine, Detroit, MI, USA
| | - Vamsi Kodali
- Degenerative Disease Research Center, Sanford
- Burnham Medical Research Institute La Jolla, CA 92037, USA
| | - Randal J Kaufman
- Degenerative Disease Research Center, Sanford
- Burnham Medical Research Institute La Jolla, CA 92037, USA
| |
Collapse
|
21
|
Fribley AM, Cruz PG, Miller JR, Callaghan MU, Cai P, Narula N, Neubig RR, Showalter HD, Larsen SD, Kirchhoff PD, Larsen MJ, Burr DA, Schultz PJ, Jacobs RR, Tamayo-Castillo G, Ron D, Sherman DH, Kaufman RJ. Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response. ACTA ACUST UNITED AC 2011; 16:825-35. [PMID: 21844328 DOI: 10.1177/1087057111414893] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Despite advances toward understanding the prevention and treatment of many cancers, patients who suffer from oral squamous cell carcinoma (OSCC) confront a survival rate that has remained unimproved for more than 2 decades, indicating our ability to treat them pharmacologically has reached a plateau. In an ongoing effort to improve the clinical outlook for this disease, we previously reported that an essential component of the mechanism by which the proteasome inhibitor bortezomib (PS-341, Velcade) induced apoptosis in OSCC required the activation of a terminal unfolded protein response (UPR). Predicated on these studies, the authors hypothesized that high-throughput screening (HTS) of large diverse chemical libraries might identify more potent or selective small-molecule activators of the apoptotic arm of the UPR to control or kill OSCC. They have developed complementary cell-based assays using stably transfected CHO-K1 cell lines that individually assess the PERK/eIF2α/CHOP (apoptotic) or the IRE1/XBP1 (adaptive) UPR subpathways. An 66 K compound collection was screened at the University of Michigan Center for Chemical Genomics that included a unique library of prefractionated natural product extracts. The mycotoxin methoxycitrinin was isolated from a natural extract and found to selectively activate the CHOP-luciferase reporter at 80 µM. A series of citrinin derivatives was isolated from these extracts, including a unique congener that has not been previously described. In an effort to identify more potent compounds, the authors examined the ability of citrinin and the structurally related mycotoxins ochratoxin A and patulin to activate the UPR. Strikingly, it was found that patulin at 2.5 to 10 µM induced a terminal UPR in a panel of OSCC cells that was characterized by an increase in CHOP, GADD34, and ATF3 gene expression and XBP1 splicing. A luminescent caspase assay and the induction of several BH3-only genes indicated that patulin could induce apoptosis in OSCC cells. These data support the use of this complementary HTS strategy to identify novel modulators of UPR signaling and tumor cell death.
Collapse
Affiliation(s)
- Andrew M Fribley
- Carmen and Ann Adams Department of Pediatrics, Division of Hematology/Oncology, Wayne State University, 421 E. Canfield, Detroit, MI 48201, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
The historic distinction between academic- and industry-driven drug discovery, whereby academicians worked to identify therapeutic targets and pharmaceutical companies advanced probe discovery, has been blurred by an academic high-throughput chemical genomic revolution. It is now common for academic labs to use biochemical or cell-based high-throughput screening (HTS) to investigate the effects of thousands or even hundreds of thousands of chemical probes on one or more targets over a period of days or weeks. To support the efforts of individual investigators, many universities have established core facilities where screening can be performed collaboratively with large chemical libraries managed by highly trained HTS personnel and guided by the experience of computational, medicinal, and synthetic organic chemists. The identification of large numbers of promising hits from such screens has driven the need for independent labs to scale down secondary in vitro assays in the hit to lead identification process. In this chapter, we will describe the use of luminescent and quantitative reverse transcription real-time PCR (qRT-PCR) technologies that permit evaluation of the expression patterns of multiple unfolded protein response (UPR) and apoptosis-related genes, and simultaneously evaluate proliferation and cell death in 96- or 384-well format.
Collapse
Affiliation(s)
- Andrew M Fribley
- Department of Biological Chemistry, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
| | | | | | | | | |
Collapse
|
23
|
Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, Wang CY. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281:31440-7. [PMID: 16928686 DOI: 10.1074/jbc.m604356200] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cisplatin is one of the most common DNA-damaging agents used for treating patients with solid tumors such as squamous cell carcinoma (SCC). Unfortunately, significant levels of resistance in SCC cells emerge rapidly following cisplatin treatment. Here we report that the proteasome inhibitor PS-341, the representative of a new class of chemotherapeutic drugs, was capable of inducing apoptosis in cisplatin-resistant SCC cells via the endoplasmic reticulum stress. PS-341 stimulated the phosphorylation of PERK and the unfolded protein response, resulting in the induction of the transcription factor ATF-4. Importantly, the Bcl-2 homology domain 3-only (BH3-only) protein Noxa was found to be strongly induced in cisplatin-resistant SCC cells by PS-341 but not by cisplatin. The knock-down of Noxa using small interference RNA significantly abolished PS-341-mediated apoptosis in SCC cells. Using eIF2alpha mutant mouse embryonic fibroblasts, we found that functional eIF2alpha played an essential role in PS-341-induced Noxa expression. Taken together, our novel findings reveal a direct link between PS-341-induced endoplasmic reticulum stress and the mitochondria-dependent apoptotic pathway and suggest that PS-341 may be utilized for overcoming cisplatin-resistance in human SCC.
Collapse
Affiliation(s)
- Andrew M Fribley
- Laboratory of Molecular Signaling and Apoptosis, Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, MI 48109-1078, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|